DM-101PX

About Desentum

Desentum is a Finnish biotech innovator developing next-generation allergen immunotherapies using its proprietary recombinant hypoallergen technology. The company's lead candidates aim to significantly reduce treatment duration and the risk of severe adverse reactions by modifying allergens to suppress IgE-mediated histamine release. Having completed a rapid €8 million financing round in 2026, Desentum is advancing its lead program for birch pollen allergy through Phase 2 clinical trials. The company seeks to address major limitations of current AIT, positioning itself in the large and growing global allergy treatment market.

Therapeutic Areas